Unknown

Dataset Information

0

HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF-?B p65 transcriptional activity.


ABSTRACT: The increasing number of patients suffering from chronic obstructive pulmonary disease (COPD) represents a major and increasing health problem. Therefore, novel therapeutic approaches are needed. Class I HDACs 1, 2 and 3 play key roles in the regulation of inflammatory gene expression with a particular pro-inflammatory role for HDAC 3. HDAC 3 has been reported to be an important player in inflammation by deacetylating NF-?B p65, which has been implicated in the pathology of COPD. Here, we applied the pharmacological HDAC 3-selective inhibitor RGFP966, which attenuated pro-inflammatory gene expression in models for inflammatory lung diseases. Consistent with this, a robust decrease of the transcriptional activity of NF-?B p65 was observed. HDAC 3 inhibition affected neither the acetylation status of NF-?B p65 nor histone H3 or histone H4. This indicates that HDAC 3 inhibition does not inhibit NF-?B p65 transcriptional activity by affecting its deacetylation but rather by inhibiting enzymatic activity of HDAC 3. Taken together, our findings indicate that pharmacological HDAC 3-selective inhibition by inhibitors such as RGFP966 may provide a novel and effective approach toward development of therapeutics for inflammatory lung diseases.

SUBMITTER: Leus NG 

PROVIDER: S-EPMC4844503 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF-κB p65 transcriptional activity.

Leus Niek G J NG   van der Wouden Petra E PE   van den Bosch Thea T   Hooghiemstra Wouter T R WTR   Ourailidou Maria E ME   Kistemaker Loes E M LE   Bischoff Rainer R   Gosens Reinoud R   Haisma Hidde J HJ   Dekker Frank J FJ  

Biochemical pharmacology 20160316


The increasing number of patients suffering from chronic obstructive pulmonary disease (COPD) represents a major and increasing health problem. Therefore, novel therapeutic approaches are needed. Class I HDACs 1, 2 and 3 play key roles in the regulation of inflammatory gene expression with a particular pro-inflammatory role for HDAC 3. HDAC 3 has been reported to be an important player in inflammation by deacetylating NF-κB p65, which has been implicated in the pathology of COPD. Here, we applie  ...[more]

Similar Datasets

| S-EPMC5009619 | biostudies-literature
| S-EPMC5512285 | biostudies-literature
| S-EPMC9490993 | biostudies-literature
| S-EPMC9659591 | biostudies-literature
| S-EPMC6458705 | biostudies-literature
| S-EPMC10665790 | biostudies-literature
| S-EPMC8891143 | biostudies-literature
| S-EPMC3995767 | biostudies-literature
| S-EPMC7150673 | biostudies-literature
| S-EPMC10903333 | biostudies-literature